Streetbeat News

Regulatory

TRVN

Trevena, Inc. has been granted a U.S. patent (11,912,713) for delta-opioid receptor modulating compounds, aimed at treating pain, migraines, depression, Parkinson's disease, and other disorders. This patent covers the methods of using and making these compounds.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:33 pm

SPY

U.S. President Biden emphasized the urgency of finding a solution to fund the government and support Ukraine, stating the situation is dire. During a meeting with Congress leaders, he highlighted that a government shutdown would significantly damage the economy.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 4:47 pm

MSFT

QCOM

Microsoft and Qualcomm face regulatory scrutiny over their AI and acquisition endeavors, respectively. Microsoft's investment in Mistral AI and partnership with OpenAI are under the EU and UK's watch, potentially affecting its AI projects. Qualcomm's acquisition of Autotalks is being investigated by the UK's CMA and the EU, raising competition concerns. Nvidia, Intel, and their respective merger plans have also faced regulatory opposition.

Portfolio Pulse from Anusuya Lahiri

February 27, 2024 | 4:33 pm

IFBD

JANX

LOW

NERV

NRXP

TWKS

VKTX

Nasdaq rose by 50 points as Lowe's Companies Inc (LOW) reported better-than-expected Q4 results, with sales of $18.60 billion and EPS of $1.77. Lowe's anticipates FY24 revenue of $84-$85 billion and adjusted EPS of $12.00-$12.30. Janux Therapeutics (JANX), Infobird Co. (IFBD), and Viking Therapeutics (VKTX) saw significant stock increases due to positive clinical data and market volatility. Conversely, Minerva Neurosciences (NERV), Thoughtworks Holding (TWKS), and NRx Pharmaceuticals (NRXP) experienced substantial declines due to regulatory setbacks and disappointing financial results.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 2:42 pm

GLD

IWM

META

NVDA

USO

UUP

The article discusses the potential impact on markets if the Federal Reserve does not cut interest rates in 2024, considering recent inflation data and labor market strength. It highlights risks from supply chain issues, wage growth, and fiscal policy challenges. The iShares Russell 2000 ETF (IWM), Nvidia Corporation (NVDA), Meta Platforms Inc (META), the Invesco Dollar Index Bullish Fund (UUP), the SPDR Gold Shares ETF (GLD), and the United States Oil Fund ETF (USO) are mentioned in relation to their potential reactions to prolonged high interest rates.

Portfolio Pulse from Neil Dennis

February 27, 2024 | 2:42 pm

NERV

Minerva Neurosciences' stock is trading lower following the FDA's issuance of a Complete Response Letter for the New Drug Application of roluperidone, intended to treat negative symptoms in schizophrenia patients.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 2:31 pm

IFBD

Infobird Co Ltd (NASDAQ:IFBD) shares surged by 148% to $6.85 due to volatility following an unexpected delay in its planned reverse stock split, now rescheduled from February 26 to March 4 due to regulatory clearances. The article also provides guidance on how to buy IFBD stock or bet against it.

Portfolio Pulse from Henry Khederian

February 27, 2024 | 2:19 pm

KNW

Know Labs, Inc. (NYSE:KNW) announced the KnowU, a wearable non-invasive continuous glucose monitor (CGM), incorporating a proprietary sensor intended for FDA submission. The KnowU, smaller and lighter than its prototype, features on-board computing, built-in machine learning, and aims to enhance diabetes management by being durable, eliminating disposables, and offering easy connectivity with a mobile app. Know Labs plans to use the KnowU for accelerated data collection in FDA clinical trials, targeting a diverse range of glycemic levels and populations. The company, holding over 270 patents, aims to make diabetes care more accessible and affordable.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 2:02 pm

EEIQ

EpicQuest Education Group International Limited (NASDAQ: EEIQ) announced that Davis University received HLC approval for two new STEM programs, expected to significantly increase revenue from students in India and China. The company plans to double the number of students from China and sees India as a significant revenue source, especially with the US being a top choice for Indian students. The recent opening of a recruiting office in Sri Lanka aims to attract students from Southeast Asia and the Middle East. Previously, HLC approved Davis University's online programs, indicating no further approvals are needed for online education.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:49 pm

ICU

SeaStar Medical Holding Corporation (NASDAQ:ICU) announced the publication of a manuscript in the European Journal of Heart Failure discussing the potential of its Selective Cytopheretic Device (SCD) in treating heart failure patients with hyperinflammation. The manuscript highlights the device's role in reducing systemic inflammation, potentially enabling heart failure patients to receive life-saving treatments like LVADs or heart transplants. The Adult SCD, part of the Quelimmune product family, received Breakthrough Device Designation from the FDA for cardiorenal syndrome in September 2023. Additionally, SeaStar Medical recently announced FDA approval for the Pediatric SCD for children with acute kidney injury due to sepsis.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:47 pm